Patient characteristics
| Parameter . | Value . |
|---|---|
| Median age, y (range) | 56 (21-68) |
| Male-female (%) | 18 (60)/12 (40) |
| FAB classification, no. (%) | |
| AML M1 | 8 (27) |
| AML M2 | 12 (40) |
| AML M4 | 4 (13) |
| AML M5 | 2 (7) |
| Unclassified | 4 (13) |
| Karyotype, no. (%)* | |
| Good | 1 (3) vs 1 (3) |
| Intermediate | 12 (40) vs 7 (23) |
| Poor | 17 (57) vs 16 (53) |
| Unknown | 0 (0) vs 6 (20) |
| Median bone marrow blasts, % (range)* | 62 (22-98) vs 67 (11-94) |
| Median peripheral blood blasts, % (range)* | 22 (0-97) vs 29 (0-97) |
| Median white blood cells, 103/μL (range)* | 18 (1-301) vs 8 (1-126) |
| Median hemoglobin, g/dL (range)* | 9.4 (6.8-13.0) vs 9.8 (7.9-13.7) |
| Median platelets, 103/μL (range)* | 46 (9-264) vs 40 (1-146) |
| Median overall survival, mo (range) | 18 (8-80) |
| Median time from diagnosis to relapse, mo (range) | 11 (3-30) |
| Median time from relapse to death, mo (range) | 6 (0-65) |
| Parameter . | Value . |
|---|---|
| Median age, y (range) | 56 (21-68) |
| Male-female (%) | 18 (60)/12 (40) |
| FAB classification, no. (%) | |
| AML M1 | 8 (27) |
| AML M2 | 12 (40) |
| AML M4 | 4 (13) |
| AML M5 | 2 (7) |
| Unclassified | 4 (13) |
| Karyotype, no. (%)* | |
| Good | 1 (3) vs 1 (3) |
| Intermediate | 12 (40) vs 7 (23) |
| Poor | 17 (57) vs 16 (53) |
| Unknown | 0 (0) vs 6 (20) |
| Median bone marrow blasts, % (range)* | 62 (22-98) vs 67 (11-94) |
| Median peripheral blood blasts, % (range)* | 22 (0-97) vs 29 (0-97) |
| Median white blood cells, 103/μL (range)* | 18 (1-301) vs 8 (1-126) |
| Median hemoglobin, g/dL (range)* | 9.4 (6.8-13.0) vs 9.8 (7.9-13.7) |
| Median platelets, 103/μL (range)* | 46 (9-264) vs 40 (1-146) |
| Median overall survival, mo (range) | 18 (8-80) |
| Median time from diagnosis to relapse, mo (range) | 11 (3-30) |
| Median time from relapse to death, mo (range) | 6 (0-65) |
Values shown represent diagnosis versus relapse.